Let’s glance at the details Why Evelo Biosciences, Inc. (EVLO) shares surged dramatically in ‎the AH trading

After-hours trading on Friday, Evelo Biosciences, Inc. (Nasdaq: EVLO), the stock plunged -11/56% to $10.25. It’s not clear what happened that caused the share price to fall, and investors may want to take that as a warning sign.

A clinical-stage biotechnology company creating new oral medications with systemic effects prioritizes EDP1908 as its lead clinical candidate in oncology.

Discover Tomorrow's Stocks Today!

When it comes to discovering hidden gems within the stock market, Stock Wire News has consistently provided invaluable insights. Stock Wire News invites you to explore their upcoming Wealth Building Report. This report will shine a spotlight on little-known companies with the potential for substantial growth in 2024, and it's completely FREE for a limited time.

Claim the free report now by clicking here and start discovering the hidden gems of the market

The Company said that it would cease patient recruitment for Phase 1/2 clinical trial of EDP1503 and finalize the study.

Read More

It revealed on additional interim clinical data from EDP1503, treated with pembrolizumab in TNBC patients with its Phase 1/2 open study, were presented in a poster session at the San Antonio Breast Cancer Symposium (SABCS) 2020 Virtual Meeting. In the 12 patients who received EDP1503 at a higher dose, as of a cutoff date of October 30, 2020, the response rate was 17 percent, with a disease control rate of 25%.

It suggests that the small intestinal axis, SINTAXTM, can be targeted using oral, gut-restricted medicines.

Most Popular

Related posts